PANEL: Pre-approval Access for rare diseases, current considerations
Wednesday, November 4, 2020 1:10 PM to 2:10 PM · 1 hr. (Africa/Abidjan)
Access & Pricing
Information
- What are strategic considerations for Expanded Access within the rare diseases space?
- What are recent developments and experiences with Expanded Access within the EU?
- How can EA Pathways can be supportive of high-cost therapies - some new developments here?
- What would be the role of Real-World Data – any considerations?
- What are key learnings from COVID-19 as an industry?
- Any regulatory trends that would be supportive of pre-approval strategies for Pharmaceutical companies?
